Shares of Bio-Techne Corp. slipped 7.27% to $47.86 Wednesday, on what proved to be an all-around mixed trading session for ...

Revisions to classification criteria ‘will ensure homogeneous trial populations’ with data-driven scoring, a standardized MRI ...

In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or ...

Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen ...

The Dow Jones Industrial Average is falling Wednesday morning with shares of Amgen and 3M delivering the stiffest headwinds for the blue-chip average. ‘We started worse than broke.’ Now at 64 and 65, ...

Kiyan Anthony, 18, followed in his father's footsteps when he announced his commitment to play for Syracuse basketball on ...

While M&A activity slowed in the first quarter of 2025, including in life sciences, there have been plenty of noteworthy developments in the ...

Leandro Boer, MD, PhD, VP, US general medicines, Amgen, discusses new real-world data showing that most high-risk ...

The Unified Patent Court (UPC) has quickly become an important forum for pharmaceutical and biotech patent disputes in Europe ...

Served on Celgene's Executive Committee and played a key leadership role in the BMS transaction, the integration of Celgene into BMS, and the divestiture of Otezla® to Amgen Appointment marks a key ...

The VanEck Biotech ETF offers lower risk with established companies, but 23% of AUM in speculative stocks poses a risk. Check ...